rs63751004
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PP1PM2_SupportingPS3PP3_ModeratePP4_Moderate
This summary comes from the ClinGen Evidence Repository: The NM_000251.3:c.1012G>A variant in MSH2 is a missense variant predicted to cause substitution of Glycine to Arginine at amino acid 338 (p.Gly338Arg). The prior probability for pathogenicity of this missense variant is 0.96 according to http://priors.hci.utah.edu/PRIORS (PP3_moderate). This variant has been identified in at least two independent patients with CRC: one tumor with loss of MSH2 and MSH6 protein expression and one tumour with loss of MSH2 protein expression (PP4_moderate). Results of functional and segregation odds support the evidence of pathogenicity of the variant (PS3 and PP1). This variant is absent from gnomAD v2.1.1 and gnomAD v4.1 (PM2_supporting).In summary, this variant meets the criteria to be classified as pathogenic for Lynch Syndrome, based on the MMR gene specific ACMG/AMP criteria established by the ClinGen InSiGHT Hereditary Colorectal Cancer/ Polyposis VCEP: PP3_Mod, PP4_Mod, PS3, PP1 and PM2_Sup (VCEP specifications version 1) LINK:https://erepo.genome.network/evrepo/ui/classification/CA016843/MONDO:0005835/137
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, G2P
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000251.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | MANE Select | c.1012G>A | p.Gly338Arg | missense | Exon 6 of 16 | NP_000242.1 | P43246-1 | ||
| MSH2 | c.1012G>A | p.Gly338Arg | missense | Exon 6 of 18 | NP_001393603.1 | ||||
| MSH2 | c.1012G>A | p.Gly338Arg | missense | Exon 6 of 18 | NP_001393560.1 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | TSL:1 MANE Select | c.1012G>A | p.Gly338Arg | missense | Exon 6 of 16 | ENSP00000233146.2 | P43246-1 | ||
| MSH2 | TSL:1 | c.1012G>A | p.Gly338Arg | missense | Exon 6 of 16 | ENSP00000384199.1 | E9PHA6 | ||
| MSH2 | c.1063G>A | p.Gly355Arg | missense | Exon 7 of 17 | ENSP00000588166.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at